Treatment Of Metastatic Bladder Cancer at the Time Of Biochemical reLApse Following Radical Cystectomy

NCT04138628 | Active Not Recruiting Phase 2 DMC

• 2 other identifiers: DaBlaCa-142019-001679-36
• Study Type: interventional
• Target: 154
• Locations: 1 country
• Sites: 5

Brief Summary

Immunotherapy (checkpoint inhibitors) is approved as first and second line treatment to patients with metastatic bladder cancer. However, response rates are low and no biomarkers have yet shown strong predictive value for patient selection. Moreover, the term 'metastatic' is based on metastases visible on conventional CT scans and, thus, require a certain size of tumour load. Clinical trials are currently being conducted that investigate the use of adjuvant immunotherapy for this group of patients (treatment to all), which will result in massive over-treatment and huge costs to the healthcare system. This project has the primary objective to identify new indications for initiating immunotherapy in patients with metastatic bladder cancer. Sensitive molecular techniques for detection of tumor DNA in the blood will be used to identify patients with early signs of metastatic disease. In addition, comprehensive biomarker analysis will be performed to identify predictors of treatment response.

Conditions

Bladder Cancer; Bladder Cancer, Metastatic

Keywords

Muscle Invasive Bladder Cancer (MIBC); biomarkers; ctDNA; immunotherapy; circulating tumor DNA; liquid biopsies

Outcome Measures

Primary Outcomes (1)

• Complete response (CR) after treatment with investigational agent initiated by ctDNA positive status after radical cystectomy (with or without concomitant visible metastases on CT).

  CR in the current study is defined as ctDNA negative status combined with regular imaging (CT) after treatment. Thus, any metastasis visible on CT at the time of treatment initiation should undergo complete response. In Study Subjects without visible metastasis on CT at the time of treatment, initiation should result in unchanged status on CT. Data will be compared to available historical data on response to PD-1 / PD-L1 targeted agents.

  Time from treatment initiation with investigational agent until 12 months after initiation

Secondary Outcomes (7)

• Duration of freedom from clinical relapse in Study Subjects showing decrease or stabilization of ctDNA level after treatment with investigational agent

  12 months

• Overall survival after cystectomy in Study Subjects having biochemical relapse

  5 years

• Cancer specific survival after cystectomy in Study Subjects having biochemical relapse

  5 years

• Recurrence free survival after cystectomy in Study Subjects having biochemical relapse

  5 years

• Cancer specific survival after cystectomy in Study Subjects having biochemical relapse stratified for potential predictive biomarkers for response to treatment

  5 years

Study Arms (1)

ctDNA screening arm

EXPERIMENTAL

Flat dose 1200 mg Atezolizumab every three weeks for up to 13 months

Drug: Atezolizumab

Interventions

Atezolizumab DRUG

The study drug will be given according to current recommendations as systemic treatment every third week for 12 months or until progression. Treatment will be initiated within 28 days of detection of ctDNA.

ctDNA screening arm

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• ≥18 years of age at the time of signing the Informed Consent Form
• For male study subjects: agreement to remain abstinent (refrain from heterosexual intercourse) or use a condom, and agreement to refrain from donating sperm.
• Signed Informed Consent Form
• ECOG PS 0, 1 or 2
• Is, according to the Investigator's judgement, able to comply with the trial protocol
• Ability to understand the Participant Information Sheet orally and in writing
• Preoperative PET/CT of thorax, abdomen, and pelvis with no suspicion of organ metastases or lymph node metastasis\* above the aortic bifuraction
• Study Subjects undergoing radical cystectomy due to histologically documented muscle invasive urothelial carcinoma (including subtypes) stage cT2-4a in the urinary bladder following NAC\*\* in cisplatin-fit Study Subjects.
• Study Subjects who have undergone down-staging chemotherapy because of lymph node metastasis with no organ metastases can be included if complete response regarding lymph nodes are identified on preoperative imaging.
• NAC includes Study Subjects who have stopped after one course of chemotherapy because of side effects or local non-metastatic progression

You may not qualify if:

• Subjects undergoing non-radical cystectomy for palliative reasons
• Non-radical surgery estimated intraoperative
• Other histology of BC than urothelial carcinoma - mixed tumours with urothelial features are allowed
• Concomitant invasive cancer within 5 years other than non-melanoma skin cancer and prostate cancer without metastasis
• Known contraindication to immunotherapy
• A history of autoimmune disease. Study Subjects with vitiligo, type I diabetes mellitus, residual hypothyroidism due to autoimmune condition only requiring hormone replacement, psoriasis not requiring systemic treatment, or conditions not expected to recur in the absence of an external trigger are permitted to enroll. Subjects with a condition requiring systemic treatment with either corticosteroids (\> 10 mg daily prednisone equivalents) or other immunosuppressive medications within 14 days of study drug administration. Inhaled or topical steroids and adrenal replacement doses \> 10 mg daily prednisone equivalents are permitted in the absence of active autoimmune disease.
• Study Subjects who meet any of the following criteria will be excluded from study entry:
• History of idiopathic pulmonary fibrosis, organizing pneumonia (e.g., bronchiolitis obliterans), drug-induced pneumonitis, or idiopathic pneumonitis, or evidence of active pneumonitis on screening chest computed tomography (CT) scan
• Treatment with systemic immunostimulatory agents (including, but not limited to, interferon and interleukin 2 \[IL-2\]) within 4 weeks or 5 drug elimination half-lives (whichever is longer) prior to initiation of study treatment
• HIV positive
• History of pneumonitis (History of radiation pneumonitis in the radiation field (fibrosis) is permitted.
• Hepatitis B or hepatitis C infection
• Subjects who have received a live, attenuated vaccine within 28 days prior to enrolment

Sponsors & Collaborators

• Aarhus University Hospital: collaborator
• Jørgen Bjerggaard Jensen: lead
• Herlev Hospital: collaborator
• Rigshospitalet, Denmark: collaborator
• Odense University Hospital: collaborator
• Aalborg University Hospital: collaborator

Study Sites (5)

Aalborg Universitetshospital

Aalborg, 9100, Denmark

Location

Aarhus University Hospital

Aarhus, 8200, Denmark

Location

Rigshospitalet

Copenhagen, 2100, Denmark

Location

Herlev Hospital

Herlev, 2730, Denmark

Location

Odense Universitetshospital

Odense, 5000, Denmark

Location

MeSH Terms

Conditions

Urinary Bladder Neoplasms; Neoplasm Metastasis

Interventions

atezolizumab

Condition Hierarchy (Ancestors)

Urologic Neoplasms; Urogenital Neoplasms; Neoplasms by Site; Neoplasms; Female Urogenital Diseases; Female Urogenital Diseases and Pregnancy Complications; Urogenital Diseases; Urinary Bladder Diseases; Urologic Diseases; Male Urogenital Diseases; Neoplastic Processes; Pathologic Processes; Pathological Conditions, Signs and Symptoms

Study Officials

• Jørgen B Jensen, Professor

  Dept. Of Urology, Aarhus University Hospital, Denmark

  PRINCIPAL INVESTIGATOR

• Lars Dyrskjøt, Professor

  Dept. Of Molecular Medicine (MOMA) Aarhus University Hospital, Denmark

  STUDY CHAIR

• Mads Agerbæk, MD

  Dept. Of Oncology, Aarhus University Hospital, Denmark

  PRINCIPAL INVESTIGATOR

• Karin Birkenkamp-Demtröder, Ass. professor

  Dept. Of Molecular Medicine (MOMA) Aarhus University Hospital, Denmark

  STUDY CHAIR

Study Design

• Study Type: interventional
• Phase: phase 2
• Allocation: NA
• Masking: NONE
• Purpose: DIAGNOSTIC
• Intervention Model: SINGLE GROUP
• Sponsor Type: OTHER
• Responsible Party: SPONSOR INVESTIGATOR
• PI Title: MD, DMSc, Professor, Consultant in Urology

Model Details: Single country Investigator Initiated, Open-label, Single-arm, Non-randomized, Phase II study

Study Record Dates

• First Submitted: October 23, 2019
• First Posted: October 24, 2019
• Study Start: March 24, 2020
• Primary Completion: August 1, 2024
• Study Completion (Estimated): November 1, 2030
• Last Updated: March 2, 2026

Record last verified: 2026-02

Data Sharing

• IPD Sharing: Will not share

Locations

DK (5)